LAUREN SMITH: Open Payments
NPI 1962102087 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,126 in 68 payments from 15 companies in 2025. Trend: 2023 $686 · 2024 $742 · 2025 $1,126
Food & beverage: $1,126
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $262 |
| Lilly USA, LLC | 11 | $189 |
| ABBVIE INC. | 12 | $187 |
| SHIELD THERAPEUTICS INC | 5 | $88 |
| Novo Nordisk Inc | 5 | $83 |
| Phathom Pharmaceuticals, Inc. | 7 | $73 |
| Stryker Corporation | 4 | $73 |
| PFIZER INC. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
Products named: FARXIGA, LINZESS, ZEPBOUND, ACCRUFER, VOQUEZNA, MOUNJARO, ARTIX MT, Ozempic.
Industry payments across MS — which companies pay providers there.
